secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2025-07-22T23:59:59+00:00
Accession:  0001558370-25-009352
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Fast Track for PMN310; ATM program terminated after minimal sales
----------------------------------------------------------------------------

- FDA granted Fast Track Designation to PMN310 for Alzheimer's disease.
- DSMB approved dose escalation to second 10 mg/kg cohort in Phase 1b trial (May 2025).
- No cases of ARIA (brain swelling/microhemorrhages) observed as of July 21, 2025.
- ATM program with BTIG terminated; only $190,274 raised of $25M available (75,862 shares sold).
- No termination penalties; no further shares will be sold under the program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025009352/0001558370-25-009352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025009352/pmn-20250721x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-009352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer